Drugs / CF33-CD19
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06063317 | Oct 2023 → Feb 2026 | cancer | Imugene Limited | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CF33-CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06063317 ↗ |
| Known as | onCARlytics | “A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab” NCT06063317 ↗ |
| Route | Other | “administered intratumorally” NCT06063317 ↗ |